1.

Identification and validation of novel therapeutic or diagnostic targets, focusing on transformation mechanisms using a range of hematopathy models, including those mimicking pre-leukemia stages.

a. Identification and preclinical confirmation

b. Animal models and in vivo validation

c. Drug design

2.

Screening and treatment efficacy validation 

a. Screening and/or repositioning of existing drugs or their combinations

b. Pharmacodynamic and efficacy biomarkers

c. Mechanisms of resistance, effect on hemopathy-initiating cells

3.

Accelerated delivery of preclinical and clinical proofs of concept

a. Technological innovations (in-vitro, ex-vivo, in-vivo)

b. Methodological innovations: biostatistical approaches, protocol design

c. Professionalizing clinical research in terms of early-phase trials

4.

Enhancing the value of biomedical data and biological resources

a. Organization and pooling of databases and collections

b. Leveraging massive data with artificial intelligence

c. Development of synthetic reference cohorts